11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Avian H7 is one of several influenza A virus subtypes that have the potential to cause pandemics. Herein we describe preclinical results following administration of an investigational H7N1 inactivated detergent-split virion vaccine adjuvanted with the AS03 Adjuvant System. The adjuvanted H7N1 vaccine was highly immunogenic compared to the non-adjuvanted H7N1 vaccine in unprimed mice with less than 100ng of hemagglutinin antigen per dose. In addition, compared to the non-adjuvanted vaccine, the AS03-adjuvanted H7N1 vaccine also induced robust HI and VN antibody responses that cross-reacted with other H7 subtypes, including recently emerged H7N9 virus. These H7 data from the preclinical mouse model add to the existing H5 data to suggest that AS03 adjuvant technology may be generally effective for formulating antigen-sparing detergent-split virion vaccines against intrinsically sub-immunogenic avian influenza A virus subtypes.

          Related collections

          Author and article information

          Journal
          Vaccine
          Vaccine
          Elsevier BV
          1873-2518
          0264-410X
          Jul 31 2015
          : 33
          : 32
          Affiliations
          [1 ] GSK Vaccines, Laval, QC, Canada. Electronic address: corey.p.mallett@gsk.com.
          [2 ] GSK Vaccines, Laval, QC, Canada. Electronic address: edith.r.beaulieu@gsk.com.
          [3 ] GSK Vaccines, Laval, QC, Canada. Electronic address: marie-helene.a.joly@gsk.com.
          [4 ] GSK Vaccines, Rixensart, Belgium. Electronic address: benoit.baras@gsk.com.
          [5 ] Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: xal0@cdc.gov.
          [6 ] Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: hdy2@cdc.gov.
          [7 ] Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: mwl2@cdc.gov.
          [8 ] Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: jmk9@cdc.gov.
          [9 ] GSK Vaccines, King of Prussia, PA, United States. Electronic address: bruce.2.innis@gsk.com.
          [10 ] GSK Vaccines, Rixensart, Belgium. Electronic address: sandra.giannini@gsk.com.
          Article
          S0264-410X(15)00842-7
          10.1016/j.vaccine.2015.06.053
          26100923
          5dca6fde-dbb2-4ffc-beaa-ef9a6b5ae7b4
          History

          Unprimed mouse immunogenicity model,H7N1influenza vaccine,AS03 Adjuvant System,Avian H7 subtype influenza viruses

          Comments

          Comment on this article